BibTex RIS Cite

Hepatitis B immune globulin and HBV-related liver transplantation

Year 2016, , 38 - 42, 01.08.2016

Sinan Akay Zeki Karasu

https://doi.org/10.5472/MMJsi.2901.08

Abstract

The risk of recurrence of liver cirrhosis and hepatocellularcarcinoma due to hepatitis B virus (HBV) infection was 90%following liver transplantation before 1990’s but now we rarelysee recurrence due to the highly effective prophylactic treatments.In this review, we discussed the achievements of the prophylactictreatments in patients transplanted for HBV diseases. Options forhyperimmune globulin usage and high genetic barier anti-viraldrugs can be used to prevent the recurrence.Keywords: Liver transplant, Hepatitis B hyperimmune globulin,Recurrence

References

  • Poland GA, Jacobson RM. Clinical practice: prevention of
  • hepatitis B with the hepatitis B vaccine. N Engl J Med 2004
  • 2832-38.
  • Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting
  • list registration for liver transplantation for viral hepatitis in
  • the United States. Gastroenterology 2009; 137:1680–6.
  • Villamil FG. Prophylaxis with anti-HBs immune globulins
  • and nucleoside analogues after liver transplantation for HBV
  • infection.
  • J Hepatol 2003; 39: 466-74.
  • Samuel D, Bismuth A, Mathieu D, et al. Passive
  • immunoprophylaxis after liver transplantation in HBsAgpositive
  • patients. Lancet 1991; 337: 813-5.
  • Lauchart W, Muller R, Pichlmayr R. Long-term
  • immunoprophylaxis of hepatitis B virus reinfection in
  • recipients of human liver allografts. Transplant Proc 1987
  • 4051-3.
  • Lok A. Prevention of recurrent hepatitis B post-liver
  • transplantation. Liver Transpl 2002; 8: S67-73.
  • Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy
  • is effective in suppressing hepatitis B virus after liver
  • transplantation. Gastroenterology 2011; 141: 1212-9.
  • Previsani N, Lavanchy D, Zuckerman AJ. Hepatitis B. Viral
  • hepatitis. In: Mushawar IK, editor. Perspectives in Medical
  • Virology, vol. 10. Amsterdam: Elsevier, 2004: 31-98.
  • McGory RW, Ishitani MB, Oliveira WM, et al. Improved
  • outcome of orthotopic liver transplantation for chronic
  • hepatitis B cirrhosis with aggressive passive immunization.
  • Transplantation 1996; 61: 1358-64.
  • Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver
  • transplant recipients using a fixed dosing schedule of hepatitis
  • B immunoglobulin. Hepatology 1996; 24: 1327-33.
  • Angus PW, Mc Caughan GW, Gane EJ, Crawford DH, Harley
  • H. Combination low-dose hepatitis B immune globulin and
  • lamivudine therapy provides effective prophylaxis against
  • posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
  • Gane EJ, Angus PW, Strasser S, et al. Australasian liver
  • transplant study group. Lamivudine plus low-dose hepatitis
  • B immunoglobulin to prevent recurrent hepatitis B following
  • liver transplantation. Gastroenterology 2007; 132: 931-37.
  • Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of
  • hepatitis B and C virus infections and risk factors in Turkey
  • a fieldwork TURHEP study. Clin Microbiol Infect 2015
  • 21:1020-6.
  • Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B
  • immune globulin and higher-dose lamivudinee combination to
  • prevent hepatitis B virus recurrence after liver transplantation.
  • Antivir Ther 2004 ;9:921-7.
  • Karasu Z, Akyildiz M, Kilic M, et al. Living donor liver
  • transplantation for hepatitis B cirrhosis. J Gastroenterol
  • Hepatol 2007; 22: 2124-9.
  • Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis
  • B recurrence after withdrawal of long-term hepatitis B
  • immunoglobulin in patients receiving maintenance nucleos(t)
  • ide analogue therapy. Liver Transpl 2007; 13: 374-81.
  • Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
  • of emtricitabine/tenofovir disoproxil fumarate after hepatitis
  • B immunoglobulin withdrawal after liver transplantation.
  • Liver transplantation : official publication of the American
  • Association for the Study of Liver Diseases and the
  • International Liver Transplantation Society 2013;19:594-
  • Kim YK, Kim SH, Lee SD, Park SJ. Clinical outcomes
  • and risk factors of hepatitis B virus recurrence in patients
  • who received prophylaxis with entecavir and hepatitis B
  • immunoglobulin following liver transplantation. Transplant
  • Proc 2013; 45: 3052-6.
  • Na GH, Kim DG, Han JH, et al. Prevention and risk factors of
  • hepatitis B recurrence after living donor liver transplantation.
  • J Gastroenterol Hepatol 2014; 29: 151-6.
  • Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of
  • prophylaxis with entecavir and hepatitis B immunoglobulin
  • in preventing hepatitis B recurrence after living-donor liver
  • transplantation. Hepatol Res 2013; 43: 67-71.
  • Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, et
  • al. Efficacy and safety of entecavir and/or tenofovir for
  • prophylaxis and treatment of hepatitis B recurrence post-liver
  • transplant. Transplant Proc 2010; 42: 3167-8.
  • Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
  • of emtricitabine/tenofovir disoproxil fumarate after hepatitis
  • B immunoglobulin withdrawal after liver transplantation.
  • Liver Transpl 2013; 19: 594-601.
  • Teperman LSJ, Poordad F, Schiano T, et al. Randomized trial
  • of emtricitabine/tenofovir DF plus/minus HBIG withdrawal
  • in prevention of chronic hepatitis B recurrence post-liver
  • transplantation: 48 week results. Abstract presented at
  • American Transplant Congress, Philadelphia, 2011.
  • Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)
  • ide analogue monoprophylaxis after cessation of hepatitis B
  • immunoglobulin is effective against hepatitis B recurrence.
  • Transpl Int 2014;27:1022–8.
  • Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10
  • years after liver transplantation despite successful anti-HBs
  • passive immunoprophylaxis. Hepatology 2003;38:86-95.
  • Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus
  • PW. Combination of lamivudine and adefovir without
  • hepatitis B immune globulin is safe and effective prophylaxis
  • against hepatitis b virus recurrence in hepatitis b surface
  • antigen-positive liver transplant candidates. Liver Transpl
  • 19:268–74.
  • Fung J, Chan SC, Cheung C, et al. Oral nucleoside/
  • nucleotide analogs without hepatitis B immune globulin
  • after liver transplantation for hepatitis B. Am J Gastroenterol
  • 108:942–948.
  • Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J
  • Fong TL.Nucleoside-nucleotide analog combination therapy
  • is effective in preventing recurrent hepatitis B after liver
  • transplantation. Dig Dis Sci 2015 ;60:2807-12.
  • Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy
  • and safety of entecavir versus adefovir in chronic hepatitis
  • B patients with hepatic decompensation: a randomized openlabel
  • study. Hepatology 2011;54:91–100.
  • Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon
  • E, Colombo M. Low resistance to adefovir combined with
  • lamivudine: a 3-year study of 145 lamivudine-resistant
  • hepatitis B patients. Gastroenterology 2007;133: 1445–51.

Hepatitis B immune globulin and HBV-related liver transplantation

Year 2016, , 38 - 42, 01.08.2016

Sinan Akay Zeki Karasu

https://doi.org/10.5472/MMJsi.2901.08

Abstract

The risk of recurrence of liver cirrhosis and hepatocellularcarcinoma due to hepatitis B virus (HBV) infection was 90%following liver transplantation before 1990’s but now we rarelysee recurrence due to the highly effective prophylactic treatments.In this review, we discussed the achievements of the prophylactictreatments in patients transplanted for HBV diseases. Options forhyperimmune globulin usage and high genetic barier anti-viraldrugs can be used to prevent the recurrence.Keywords: Liver transplant, Hepatitis B hyperimmune globulin,Recurrence

Keywords

Karaciğer transplantasyonu Hepatit B hyperimmun globulin Nüks

References

  • Poland GA, Jacobson RM. Clinical practice: prevention of
  • hepatitis B with the hepatitis B vaccine. N Engl J Med 2004
  • 2832-38.
  • Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting
  • list registration for liver transplantation for viral hepatitis in
  • the United States. Gastroenterology 2009; 137:1680–6.
  • Villamil FG. Prophylaxis with anti-HBs immune globulins
  • and nucleoside analogues after liver transplantation for HBV
  • infection.
  • J Hepatol 2003; 39: 466-74.
  • Samuel D, Bismuth A, Mathieu D, et al. Passive
  • immunoprophylaxis after liver transplantation in HBsAgpositive
  • patients. Lancet 1991; 337: 813-5.
  • Lauchart W, Muller R, Pichlmayr R. Long-term
  • immunoprophylaxis of hepatitis B virus reinfection in
  • recipients of human liver allografts. Transplant Proc 1987
  • 4051-3.
  • Lok A. Prevention of recurrent hepatitis B post-liver
  • transplantation. Liver Transpl 2002; 8: S67-73.
  • Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy
  • is effective in suppressing hepatitis B virus after liver
  • transplantation. Gastroenterology 2011; 141: 1212-9.
  • Previsani N, Lavanchy D, Zuckerman AJ. Hepatitis B. Viral
  • hepatitis. In: Mushawar IK, editor. Perspectives in Medical
  • Virology, vol. 10. Amsterdam: Elsevier, 2004: 31-98.
  • McGory RW, Ishitani MB, Oliveira WM, et al. Improved
  • outcome of orthotopic liver transplantation for chronic
  • hepatitis B cirrhosis with aggressive passive immunization.
  • Transplantation 1996; 61: 1358-64.
  • Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver
  • transplant recipients using a fixed dosing schedule of hepatitis
  • B immunoglobulin. Hepatology 1996; 24: 1327-33.
  • Angus PW, Mc Caughan GW, Gane EJ, Crawford DH, Harley
  • H. Combination low-dose hepatitis B immune globulin and
  • lamivudine therapy provides effective prophylaxis against
  • posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
  • Gane EJ, Angus PW, Strasser S, et al. Australasian liver
  • transplant study group. Lamivudine plus low-dose hepatitis
  • B immunoglobulin to prevent recurrent hepatitis B following
  • liver transplantation. Gastroenterology 2007; 132: 931-37.
  • Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of
  • hepatitis B and C virus infections and risk factors in Turkey
  • a fieldwork TURHEP study. Clin Microbiol Infect 2015
  • 21:1020-6.
  • Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B
  • immune globulin and higher-dose lamivudinee combination to
  • prevent hepatitis B virus recurrence after liver transplantation.
  • Antivir Ther 2004 ;9:921-7.
  • Karasu Z, Akyildiz M, Kilic M, et al. Living donor liver
  • transplantation for hepatitis B cirrhosis. J Gastroenterol
  • Hepatol 2007; 22: 2124-9.
  • Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis
  • B recurrence after withdrawal of long-term hepatitis B
  • immunoglobulin in patients receiving maintenance nucleos(t)
  • ide analogue therapy. Liver Transpl 2007; 13: 374-81.
  • Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
  • of emtricitabine/tenofovir disoproxil fumarate after hepatitis
  • B immunoglobulin withdrawal after liver transplantation.
  • Liver transplantation : official publication of the American
  • Association for the Study of Liver Diseases and the
  • International Liver Transplantation Society 2013;19:594-
  • Kim YK, Kim SH, Lee SD, Park SJ. Clinical outcomes
  • and risk factors of hepatitis B virus recurrence in patients
  • who received prophylaxis with entecavir and hepatitis B
  • immunoglobulin following liver transplantation. Transplant
  • Proc 2013; 45: 3052-6.
  • Na GH, Kim DG, Han JH, et al. Prevention and risk factors of
  • hepatitis B recurrence after living donor liver transplantation.
  • J Gastroenterol Hepatol 2014; 29: 151-6.
  • Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of
  • prophylaxis with entecavir and hepatitis B immunoglobulin
  • in preventing hepatitis B recurrence after living-donor liver
  • transplantation. Hepatol Res 2013; 43: 67-71.
  • Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, et
  • al. Efficacy and safety of entecavir and/or tenofovir for
  • prophylaxis and treatment of hepatitis B recurrence post-liver
  • transplant. Transplant Proc 2010; 42: 3167-8.
  • Teperman LW, Poordad F, Bzowej N, et al. Randomized trial
  • of emtricitabine/tenofovir disoproxil fumarate after hepatitis
  • B immunoglobulin withdrawal after liver transplantation.
  • Liver Transpl 2013; 19: 594-601.
  • Teperman LSJ, Poordad F, Schiano T, et al. Randomized trial
  • of emtricitabine/tenofovir DF plus/minus HBIG withdrawal
  • in prevention of chronic hepatitis B recurrence post-liver
  • transplantation: 48 week results. Abstract presented at
  • American Transplant Congress, Philadelphia, 2011.
  • Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)
  • ide analogue monoprophylaxis after cessation of hepatitis B
  • immunoglobulin is effective against hepatitis B recurrence.
  • Transpl Int 2014;27:1022–8.
  • Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10
  • years after liver transplantation despite successful anti-HBs
  • passive immunoprophylaxis. Hepatology 2003;38:86-95.
  • Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus
  • PW. Combination of lamivudine and adefovir without
  • hepatitis B immune globulin is safe and effective prophylaxis
  • against hepatitis b virus recurrence in hepatitis b surface
  • antigen-positive liver transplant candidates. Liver Transpl
  • 19:268–74.
  • Fung J, Chan SC, Cheung C, et al. Oral nucleoside/
  • nucleotide analogs without hepatitis B immune globulin
  • after liver transplantation for hepatitis B. Am J Gastroenterol
  • 108:942–948.
  • Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J
  • Fong TL.Nucleoside-nucleotide analog combination therapy
  • is effective in preventing recurrent hepatitis B after liver
  • transplantation. Dig Dis Sci 2015 ;60:2807-12.
  • Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy
  • and safety of entecavir versus adefovir in chronic hepatitis
  • B patients with hepatic decompensation: a randomized openlabel
  • study. Hepatology 2011;54:91–100.
  • Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon
  • E, Colombo M. Low resistance to adefovir combined with
  • lamivudine: a 3-year study of 145 lamivudine-resistant
  • hepatitis B patients. Gastroenterology 2007;133: 1445–51.
There are 115 citations in total.

Details

Subjects Clinical Sciences
Other ID JA87TY92SC
Journal Section Reviews
Authors

Sinan Akay This is me

Zeki Karasu This is me

Publication Date August 1, 2016
Published in Issue Year 2016

Cite

APA Akay, S., & Karasu, Z. (2016). Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Medical Journal, 29(2), 38-42. https://doi.org/10.5472/MMJsi.2901.08
AMA Akay S, Karasu Z. Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Med J. August 2016;29(2):38-42. doi:10.5472/MMJsi.2901.08
Chicago Akay, Sinan, and Zeki Karasu. “Hepatitis B Immune Globulin and HBV-Related Liver Transplantation”. Marmara Medical Journal 29, no. 2 (August 2016): 38-42. https://doi.org/10.5472/MMJsi.2901.08.
EndNote Akay S, Karasu Z (August 1, 2016) Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Medical Journal 29 2 38–42.
IEEE S. Akay and Z. Karasu, “Hepatitis B immune globulin and HBV-related liver transplantation”, Marmara Med J, vol. 29, no. 2, pp. 38–42, 2016, doi: 10.5472/MMJsi.2901.08.
ISNAD Akay, Sinan - Karasu, Zeki. “Hepatitis B Immune Globulin and HBV-Related Liver Transplantation”. Marmara Medical Journal 29/2 (August 2016), 38-42. https://doi.org/10.5472/MMJsi.2901.08.
JAMA Akay S, Karasu Z. Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Med J. 2016;29:38–42.
MLA Akay, Sinan and Zeki Karasu. “Hepatitis B Immune Globulin and HBV-Related Liver Transplantation”. Marmara Medical Journal, vol. 29, no. 2, 2016, pp. 38-42, doi:10.5472/MMJsi.2901.08.
Vancouver Akay S, Karasu Z. Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Med J. 2016;29(2):38-42.